HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins

Journal of the American College of Cardiology

Volumn 36, Issue 5, 2000, Pages 1691-1697

  Yang, Zhihong ^a,b   Kozai, Toshiyoki ^a,b   Van De Loo, Bernd ^a,b   Viswambharan, Hema ^a,b   Lachat, Mario ^b   Turina, Marko I ^b   Malinski, Tadeusz ^c   Lüscher, Thomas F ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c OAKLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CERIVASTATIN; CYCLIN DEPENDENT KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLATELET DERIVED GROWTH FACTOR BB; RAPAMYCIN; REGULATOR PROTEIN; WORTMANNIN;

ARTICLE; ATHEROSCLEROSIS; CELL CYCLE; CELL PROLIFERATION; CORONARY ARTERY BYPASS GRAFT; ENDOTHELIUM CELL; ENZYME INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SAPHENOUS VEIN GRAFT; VASCULAR SMOOTH MUSCLE;

CELL DIVISION; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PYRIDINES; SAPHENOUS VEIN;

EID: 0034332685     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00924-4     Document Type: Article

References (36)

1. Influence of the internal mammary-artery graft on 10-year survival and other cardiac events
2. Coronary bypass surgery with internal-thoracic-artery grafts. Effects on survival over a 15-year period
3. Difference between endothelium-dependent relaxations in arterial and in venous coronary bypass grafts
4. Different effects of thrombin receptor activation on endotheilum and smooth muscle cells of human coronary bypass vessels: Implication for venous bypass graft failure
5. Different interactions of platelets with arterial and venous coronary bypass vessels
6. The future of saphenous vein as a coronary artery bypass conduit
7. Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: Role of PDGF receptors, mitogen-activated protein kinase and cyclin-dependent kinase inhibitors
8. Signal transduction via the MAP kinases: Proceed at your own RSK
9. Lipid-regulated kinases: Some common themes at last
10. p70s6k Function is essential for G1 progression
11. G1 phase progression: Cycling on cue
12. Regulation of transcription by proteins that control the cell cycle
13. The retinoblastoma protein and cell cycle control
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Scandinavian Simvastatin Survival Study (4S)
15. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
16. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level
17. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
18. Statins do more than just lower cholesterol
19. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxylmethylglutaryl-CoA reductase
20. Coronary artery bypass graft disease
21. Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor
22. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15
23. Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study
24. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
25. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
26. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors
27. Effects of 3-hydroxyl-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
28. RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity
29. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes
30. 3-Hydroxy-3-methylglutaryl coenzyme-A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
31. 53-independent transcriptional regulation of p21WAF1/CIP1 in human prostate carcinoma cells
32. Translational control of p27Kip1 accumulation during the cell cycle
33. Geranylgeranylated Rho small GTPase(s) are essential for the degradation of p27(Kip1) and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells
34. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down-regulation of p27Kip1
35. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts